BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...
Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...
Duquesne Family Office's billionaire chief shed a trillion-dollar artificial intelligence (AI) stock in favor of a ...
Solid Biosciences (SLDB) stock surges after strong Phase 1/2 data for its Duchenne therapy SGT-003. Read more here.
Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for ...
Service utilization is the biggest factor behind spending variation, with prices, disease prevalence, and demographics ...
As of December 31, 2024, the Company had cash and cash equivalents in the amount of $15.6 million, compared to $5.3 million ...
The Tuesday decision is the latest in a string of court orders blocking or slowing President Donald Trump’s early actions.
A consumer fact sheet by the U.S. Environmental Protection ... state rules showed issues with PFOA in one of the system's ...
Drug addiction is a condition in which there is uncontrolled use of a substance with a harmful outcome. Drugs overstimulate the brain’s reward circuit, producing pleasure or euphoria. With repeated ...
The term Egyptian cotton gets thrown around a lot as shorthand for very fancy sheets, but not all Egyptian cotton is created equal. Some sheets made from Egyptian cotton will be certified as such ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback